Bloomberg Law
Free Newsletter Sign Up
Bloomberg Law
Welcome
Go
Free Newsletter Sign Up

Biogen Expects Slow Alzheimer’s Drug Uptake, May Reset Price (2)

June 23, 2021, 7:33 PM

Biogen Inc. expects gradual uptake of its new Alzheimer’s disease drug in the U.S. and said it would consider adjusting its $56,000-a-year price if the medication is taken by more patients than anticipated.

The disclosure in a company statement Wednesday is a signal the drugmaker wants to tamp down the outcry over the treatment’s potential costs to the U.S. health-care system. The company said it set the price based on the impact of the treatment and assumptions about how many people would take it.

If those turn out to be wrong, “we stand ready to work with public and private ...